The S&P 500 entered the third year of a bull market back in October and finished the year with a bang: a double-digit gain that brought the index's three-year increase to 78%. Over that time period, investors have been particularly optimistic about stocks in high-growth areas, from artificial intelligence and quantum computing to companies leading in the weight loss drug market. In this context, stocks including AI leader Nvidia, quantum innovator IonQ, and weight loss drug giant Eli Lilly each have skyroc ...

Sports quarter results out from Eli Liy. $7.54% a share beat estimates of 667 a share. Uh revenue of 19.3% billion.All right, we're going to have to figure this out. Look at that stock. Uh up 7% back over $1,000 of 17.9% billion.Um fourth quarter volumes rose 76%. Realized prices though fell 5%. Zepbound and Monaro sales more than doubled year-over-year.and those were well above expectations and that the company also uh issued upbeat fullear guidance. So it's the opposite thing we're looking for here. What ...

Core Viewpoint - The U.S. stock market experienced a collective decline, with major indices such as the Dow Jones falling by 0.34%, the Nasdaq by 1.43%, and the S&P 500 by 0.83% [1] Sector Performance - Technology stocks saw significant declines, with Broadcom dropping over 3%, and major players like Microsoft, Nvidia, and Meta each falling by more than 2% [1] - In contrast, sectors such as rare earths, non-ferrous metals, and precious metals showed strong performance, with gold resources increasing by over 20%, Southern Copper rising by more than 11%, Americas Silver up over 8%, and Pan American Silver gaining over 5% [1] - Application software, cryptocurrency, and weight loss drug stocks faced the largest declines, with Novo Nordisk falling over 14%, Coinbase and Circle each dropping over 4%, and Eli Lilly and Pfizer decreasing by more than 3% [1] Notable Company Movements - Walmart's stock rose by 2.94%, marking a significant milestone as its market capitalization surpassed the $1 trillion mark for the first time [1]

Core Insights - The weight loss market is currently dominated by two brands: Wegovy from Novo Nordisk and Zepbound from Eli Lilly, with both companies poised for further growth through new approvals [2][11] Novo Nordisk - Novo Nordisk's semaglutide, the active ingredient in Wegovy, mimics GLP-1 hormones, aiding in insulin regulation and satiety [4] - The company is seeking approval for CagriSema, a dual agonist that has shown better performance than semaglutide in clinical trials, potentially becoming a new growth driver [5] - Despite a competitive mean weight loss of 22.7% reported for CagriSema, it did not meet the company's expectations of 25% in phase 3 studies [11] - Novo Nordisk's market value has decreased by more than half over the past two years, but its pipeline may still capitalize on the expanding weight loss market [12] Eli Lilly - Eli Lilly's Zepbound is gaining market share, and the company has reported positive phase 3 results for orforglipron, a next-generation anti-obesity medication [11] - Orforglipron is a daily oral pill, making it easier for patients compared to weekly injections of Wegovy and Zepbound, which could enhance its market appeal [7][8] - The approval process for orforglipron may be expedited due to its receipt of a National Priority Voucher, potentially allowing for a quicker market entry [8] - Eli Lilly's retatrutide has demonstrated a mean weight loss of 28.7% in phase 3 studies, indicating a strong competitive position in the market [12]

Core Insights - Eli Lilly has achieved strong returns due to its advancements in weight management, positioning itself as a leader in this market [1] - The company is not resting on its laurels and continues to innovate, suggesting it may outpace competitors [1] Competitive Landscape - Novo Nordisk is the only significant competitor to Eli Lilly in the weight loss drug market, with its product Wegovy generating billions in sales [2] - Novo Nordisk is seeking label expansions and has requested FDA approval for a higher dose of semaglutide, the active ingredient in Wegovy [3][4] Product Performance - Eli Lilly's Zepbound has demonstrated superior average weight loss compared to Wegovy in clinical trials, generating $9.3 billion in revenue in the first nine months of 2025, while Wegovy generated approximately $9 billion [5] - Novo Nordisk's pipeline includes Amycretin, which is in phase 3 studies, but Eli Lilly's pipeline remains stronger with promising candidates like orforglipron and retatrutide [6][7] Market Position - Eli Lilly is clearly leading the weight loss market, with its current and future products positioning it ahead of competitors [8] - Novo Nordisk's CagriSema, which achieved a mean weight loss of 22.7%, is under regulatory review but still falls short compared to Eli Lilly's offerings [9]

Group 1: Investment Themes for 2026 - Citrini Research has identified key investment themes for 2026, focusing on automation, weight loss drugs, and female consumer spending [5][6] - The firm has developed a "Bureaucracy Score" and a "Margin Optionality Score" to screen companies that could benefit from AI-induced layoffs, indicating a bullish outlook on stocks that can reduce headcount effectively [6] Group 2: Stock Picks Related to AI Job Losses - Over thirty firms have been identified as potential beneficiaries of AI job losses, with notable mentions including Accenture, IBM Corp., Zoom Video, Target, United Parcel Service, Intuit, and Dollar General [8][6] - The focus is on companies that can streamline operations and improve profitability through automation [6] Group 3: Slop Bowl Automation - Slop bowl chains are expected to be early adopters of back-of-house automation, which will help reduce labor costs and enhance profit margins [9] - Companies like Chipotle and Cava are highlighted as likely to experience significant operational improvements due to automation [9] Group 4: Weight Loss Drug Market - The popularity of GLP-1 drugs such as Ozempic and Wegovy is creating investment opportunities for companies catering to users looking to maintain weight loss after discontinuing these medications [11] - Potential stock picks in this sector include Chipotle, Cava, Sweetgreen, Fanuc Corporation, Circus SE, and Compass Group [12]

Earlier this week, Unilver spun off its ice cream business as the Magnum Ice Cream Company, MICC, for all you home gamers, creating the first pure play ice cream stock that I can recall. Unilver announced this nearly two years ago, but to be honest, I really didn't pay a lot of attention to it. So, it took me by surprise when I came into work yesterday to see this multi-story tall banner of ice cream outside the New York Stock Exchange with free samples flowing ON THE FLOOR.KLONDIKE BARS for all. And still ...

But what Lily is trying to do today is stay competitive in the direct to consumer space for its weight loss drugs, especially following similar moves by Nova Nordis two weeks ago. And so what Lily is doing today is specifically cutting the cash price of single dose vials of Zepbound on its direct to consumer website, Lily Direct. Okay.And what's different with this compared to the Trump deal is that the Trump deal focuses on a totally different form of Zepbound, which is a multi-dosese pen that has yet to w ...

Eli Lilly announcing it will cut the prices for introductory doses of Zep found if you pay cash. This is just the latest move in the price war with Novo Nordisk that's getting more and more confusing in terms of pricing for these weight loss drugs. Joining us now to talk about it is someone who understands everything, at least in regards to this industry health.Bloomberg health reporter Madison Miller. So what do we know about Zep. LB Now it's what the five mg doses, the starter doses are going to be even c ...

What is micro doing. >> So micro doing is taking a smaller amount of these weight loss drugs than what the FDA approved. So instead of taking let's say one milligram of one of these drugs, you're taking a tenth of a milligram.The people who do this say there are a couple of reasons why they do it. First of all, it tends to be less expensive. I mean, these drugs can run you four figures a month.Another reason is fewer side effects. um they say the nausea, the stomach upset, the headaches that some people exp ...